The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Abstract
CONTEXT: Second-generation (atypical) antipsychotics (SGAs) are more expensive than first-generation (typical) antipsychotics (FGAs) but are perceived to be more effective, with fewer adverse effects, and preferable to patients. Most evidence comes from short-term efficacy trials of symptoms. OBJECTIVE: To test the hypothesis that in people with schizophrenia requiring a change in treatment, SGAs other than clozapine are associated with improved quality of life across 1 year compared with FGAs. DESIGN: A noncommercially funded, pragmatic, multisite, randomized controlled trial of antipsychotic drug classes, with blind assessments at 12, 26, and 56 weeks using intention-to-treat analysis. SETTING: Fourteen community psychiatric services in the English National Health Service. PARTICIPANTS: Two hundred twenty-seven people aged 18 to 65 years with DSM-IV schizophrenia and related disorders assessed for medication review because of inadequate response or adverse effects. INTERVENTIONS: Randomized prescription of either FGAs or SGAs (other than clozapine), with the choice of individual drug made by the managing psychiatrist. MAIN OUTCOME MEASURES: Quality of Life Scale scores, symptoms, adverse effects, participant satisfaction, and costs of care. RESULTS: The primary hypothesis of significant improvement in Quality of Life Scale scores during the year after commencement of SGAs vs FGAs was excluded. Participants in the FGA arm showed a trend toward greater improvements in Quality of Life Scale and symptom scores. Participants reported no clear preference for either drug group; costs were similar. CONCLUSIONS: In people with schizophrenia whose medication is changed for clinical reasons, there is no disadvantage across 1 year in terms of quality of life, symptoms, or associated costs of care in using FGAs rather than nonclozapine SGAs. Neither inadequate power nor patterns of drug discontinuation accounted for the result.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
(1976) · Medical Entomology and Zoology · Cited by 8,899
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
The Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome
Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.3.388 · Cited by 1,688
Multiple imputation in health‐are databases: An overview and some applications
Rubin, D. B., & Schenker, N. (1991) · Statistics in Medicine · doi:10.1002/sim.4780100410 · Cited by 1,550
A depression rating scale for schizophrenics
Addington, D., Addington, J., & Schissel, B. (1990) · Schizophrenia Research · doi:10.1016/0920-9964(90)90005-r · Cited by 1,269
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., Laughren, T. P., & Katz, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204
Cited by
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301
Wykes, T., Steel, C., Everitt, B., & Tarrier, N. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm114 · Cited by 1,029
“High CTAM 0.147 � 0.172, 0.466 8.49 (4), not significant 5 347 � 0.058, 0.782 Low CTAM 0.509 0.221, 0.797 23.04 ( 9 ), significant at the 5% level 10 520”
InfluentialTreatment and prevention of mental disorders in low-income and middle-income countries
Patel, V., Araya, R., Chatterjee, S., Chisholm, D., Cohen, A., De Silva, M., Hosman, C., McGuire, H., Rojas, G., & van Ommeren, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61240-9 · Cited by 930
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Self-citationNegative Symptoms in Schizophrenia: Avolition and Occam's Razor
Foussias, G., & Remington, G. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn094 · Cited by 594
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Increased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565
Neill, J. C., Barnes, S., Cook, S., Grayson, B., Idris, N. F., McLean, S. L., Snigdha, S., Rajagopal, L., & Harte, M. K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.004 · Cited by 530
Antipsychotic medication in schizophrenia: a review
Lally, J., & MacCabe, J. H. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldv017 · Cited by 513
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009
Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., & Dixon, L. B. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp130 · Cited by 499
Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., Ambler, D., Puglia, M., Maloney, A. E., Michael, E., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08050756 · Cited by 478
Adverse Effects of Atypical Antipsychotics: Differential Risk and Clinical Implications
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 456
Update on Typical and Atypical Antipsychotic Drugs
Meltzer, H. Y. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050911-161504 · Cited by 433
Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422
Self-citationHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Correll, C. U., Rummel-Kluge, C., Corves, C., Kane, J. M., & Leucht, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn018 · Cited by 397
The social and economic burden of treatment-resistant schizophrenia: a systematic literature review
Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836508e6 · Cited by 392
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385
The role of serotonin receptors in the action of atypical antipsychotic drugs
Meltzer, H., & Massey, B. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.02.007 · Cited by 381
Tardive dyskinesia and new antipsychotics
Correll, C. U., & Schenk, E. M. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3282f53132 · Cited by 367
ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia
Jeste, D. V., Blazer, D., Casey, D., Meeks, T., Salzman, C., Schneider, L., Tariot, P., & Yaffe, K. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301492 · Cited by 365
Olanzapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Duggan, L., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006654.pub2 · Cited by 365
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia
McClellan, J., & Stock, S. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.02.008 · Cited by 361
García, S., Martínez-Cengotitabengoa, M., López-Zurbano, S., Zorrilla, I., López, P., Vieta, E., & González-Pinto, A. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000523 · Cited by 360
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Self-citationThe past and future of delusions research: from the inexplicable to the treatable
Garety, P. A., & Freeman, D. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.126953 · Cited by 341
Zhang, J.-P., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001277 · Cited by 336
Gallego, J. A., Bonetti, J., Zhang, J., Kane, J. M., & Correll, C. U. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.03.018 · Cited by 332
Clozapine versus typical neuroleptic medication for schizophrenia
Essali, A., Al-Haj Haasan, N., Li, C., & Rathbone, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000059.pub2 · Cited by 329
Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N. (2014) · BioMed Research International · doi:10.1155/2014/656370 · Cited by 327
Samara, M. T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., & Leucht, S. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2955 · Cited by 300
Garety, P. A., Fowler, D. G., Freeman, D., Bebbington, P., Dunn, G., & Kuipers, E. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.043570 · Cited by 296
Self-citationSwartz, M. S., Perkins, D. O., Stroup, T. S., Davis, S. M., Capuano, G., Rosenheck, R. A., Reimherr, F., McGee, M. F., Keefe, R. S. E., McEvoy, J. P., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.3.428 · Cited by 291
Tardive dyskinesia and new antipsychotics
Correll, C. U., & Schenk, E. M. (2008) · Current Opinion in Internal Medicine · doi:10.1097/mci.0b013e328303e7a6 · Cited by 289
The NMDA Receptor and Schizophrenia
Balu, D. T. (2016) · Advances in Pharmacology · doi:10.1016/bs.apha.2016.01.006 · Cited by 285
Freudenmann, R. W., & Lepping, P. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00018-09 · Cited by 282
Tandon, R., Belmaker, R. H., Gattaz, W. F., Lopez-Ibor, J. J., Okasha, A., Singh, B., Stein, D. J., Olie, J.-P., Fleischhacker, W. W., & Moeller, H.-J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.033 · Cited by 276
Picchioni, M. M., & Murray, R. M. (2007) · BMJ · doi:10.1136/bmj.39227.616447.be · Cited by 266
Self-citationExtrapyramidal side-effects of antipsychotics in a randomised trial
Miller, D. D., Caroff, S. N., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., Riggio, S., Chakos, M. H., Swartz, M. S., Keefe, R. S. E., et al. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.050088 · Cited by 265
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 260
Paliperidone for schizophrenia
Dolder, C., Nelson, M., & Deyo, Z. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070261 · Cited by 254
Sendt, K.-V., Tracy, D. K., & Bhattacharyya, S. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.11.002 · Cited by 245
Schizophrenia--Time to Commit to Policy Change
Fleischhacker, W. W., Arango, C., Arteel, P., Barnes, T. R. E., Carpenter, W., Duckworth, K., Galderisi, S., Halpern, L., Knapp, M., Marder, S. R., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu006 · Cited by 214
Self-citationMovement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.
Caroff, S. N., Hurford, I., Lybrand, J., & Campbell, E. C. (2011) · Neurologic Clinics · doi:10.1016/j.ncl.2010.10.002 · Cited by 188
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
“Indeed, three separate large-scale studies indicate that the second-generation or atypical antipsychotics, which act at dopamine receptors, are no more efficacious or tolerable than first-generation typical antipsychotics (Lieberman et al. 2005; Jones et al. 2006; Sikich et al. 2008).”
BackgroundQuality of life as patient-reported outcomes: principles of assessment
Bullinger, M., & Quitmann, J. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.2/mbullinger · Cited by 158
Aripiprazole versus other atypical antipsychotics for schizophrenia
Khanna, P., Suo, T., Komossa, K., Ma, H., Rummel-Kluge, C., El-Sayeh, H. G., Leucht, S., & Xia, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006569.pub5 · Cited by 151
McEvoy, J. P., Byerly, M., Hamer, R. M., Dominik, R., Swartz, M. S., Rosenheck, R. A., Ray, N., Lamberti, J. S., Buckley, P. F., Wilkins, T. M., et al. (2014) · JAMA · doi:10.1001/jama.2014.4310 · Cited by 151
Kane, J. M., Cohen, M., Zhao, J., Alphs, L., & Panagides, J. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d35d6b · Cited by 126
Braslow, J. T., & Marder, S. R. (2019) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050718-095514 · Cited by 122
Findling, R. L., Johnson, J. L., McClellan, J., Frazier, J. A., Vitiello, B., Hamer, R. M., Lieberman, J. A., Ritz, L., McNamara, N. K., Lingler, J., et al. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.03.013 · Cited by 101
Tosh, G., Soares-Weiser, K., & Adams, C. E. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.2/gtosh · Cited by 84
Clinical Practice Guidelines for Management of Schizophrenia
Avasthi, A., Grover, S., Chakrabarti, S., & Kulhara, P. (2017) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.196972 · Cited by 75
Idris, N., Neill, J., Grayson, B., Bang-Andersen, B., Witten, L. M., Brennum, L. T., & Arnt, J. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1702-5 · Cited by 74
Systematic Overview of Cochrane Reviews for Anticholinergic Effects of Antipsychotic Drugs
Ozbilen, M., & Adams, C. E. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819a91f1 · Cited by 74
In vitro and in vivo demonstration of risperidone implants in mice
Rabin, C., Liang, Y., Ehrlichman, R. S., Budhian, A., Metzger, K. L., Majewski-Tiedeken, C., Winey, K. I., & Siegel, S. J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.08.003 · Cited by 64
Pillarella, J., Higashi, A., Alexander, G. C., & Conti, R. (2012) · Psychiatric Services · doi:10.1176/appi.ps.201100092 · Cited by 53
Yilmaz, Z., Zai, C. C., Hwang, R., Mann, S., Arenovich, T., Remington, G., & Daskalakis, Z. J. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.027 · Cited by 52
Remission as perceived by people with schizophrenia, family members and psychiatrists
Karow, A., Naber, D., Lambert, M., & Moritz, S. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.01.013 · Cited by 51
Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
Modestin, J., Wehrli, M. V., Stephan, P. L., & Agarwalla, P. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.10.018 · Cited by 38
Effectiveness of long-acting injectable antipsychotics: a clinical perspective
Castillo, E. G., & Stroup, T. S. (2015) · Evidence Based Mental Health · doi:10.1136/eb-2015-102086 · Cited by 28
Pragmatic design in randomized controlled trials
Purgato, M., Barbui, C., Stroup, S., & Adams, C. (2015) · Psychological Medicine · doi:10.1017/s0033291714001275 · Cited by 19
Metadata
- Authors
- Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2006-10-01
- Volume
- 63
- Issue
- 10
- Pages
- 1079
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2109196233
- Cited by
- 1,105
- References
- 32
- FWCI
- 69.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.